BrainStorm Cell Therapeutics Moves from Nasdaq to OTCQB Amid Delisting Notification
On July 17, 2025, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) made headlines by disclosing a significant change in its trading status. The company received a notification regarding its delisting from The Nasdaq Stock Market LLC, which stated that its common stock would be removed from the Nasdaq Capital Market. The delisting process will lead to the suspension of trading for BrainStorm's common stock starting from the open of trading on July 18, 2025.
This delisting stems from the company's failure to adhere to the Nasdaq Listing Rule 5550(b)(1), which concerns minimum shareholder equity requirements. Despite this setback, BrainStorm has already taken steps to mitigate the impact of this change. The company has secured approval to have its common stock quoted on the OTCQB Venture Market, a trading platform in the U.S. operated by OTC Markets Group. Trading on OTCQB under the same symbol, BCLI, is expected to commence at the open of trading on July 18, 2025, or shortly thereafter.
Chaim Lebovits, the CEO of BrainStorm Cell Therapeutics, commented on the situation, recognizing the challenges posed by the delisting. He expressed a commitment to their stakeholders, emphasizing that this change does not negatively affect the company's core mission nor its ongoing commitment to advance NurOwn, a promising therapy for amyotrophic lateral sclerosis (ALS) patients. The transition to OTCQB ensures that trading can continue seamlessly, allowing BrainStorm to maintain its focus on the development of NurOwn.
BrainStorm’s NurOwn technology platform represents an innovative approach to treating neurodegenerative diseases. The platform utilizes autologous mesenchymal stem cells (MSCs) that are transformed into neurotrophic factor-secreting cells (MSC-NTF cells). These MSC-NTF cells are designed to release high levels of neurotrophic factors aimed at targeting critical disease pathways in conditions like ALS. The company is gearing up for a pivotal Phase 3b trial under a Special Protocol Assessment (SPA) agreement with the FDA, which promises to advance the clinical development of NurOwn further.
In light of the recent changes, BrainStorm reassured its investors that the delisting will not hinder its business operations or ongoing research initiatives. The company commits to maintaining transparency with its shareholders by providing updates in line with SEC regulations regarding its financial status and other developments.
The transition from Nasdaq to OTCQB illustrates the dynamic nature of the biotechnology landscape, where regulatory compliance and market conditions can shift rapidly. BrainStorm has attracted attention for its ground-breaking research in ALS, which has garnered admiration in both scientific and investor circles. Its commitment to improving patient lives remains unwavering, as they navigate these challenges.
The NurOwn platform has been noted for generating critical insights into ALS, and its clinical program is at the forefront of innovation in this field. BrainStorm's research includes significant findings related to patient genomics and biomarkers, which are vital for understanding and addressing ALS more effectively.
In addition to its ALS endeavors, BrainStorm is making strides in other areas of regenerative medicine. The company is also working on an allogeneic exosome-based platform aimed at delivering therapeutic proteins and nucleic acids. Recently, BrainStorm has achieved a significant milestone with the U.S. Patent and Trademark Office granting a Notice of Allowance for a foundational patent covering its exosome technology. This development fortifies BrainStorm's intellectual property portfolio in the rapidly evolving field of regenerative medicine.
As BrainStorm transitions into its new trading environment, stakeholders are encouraged to remain vigilant and hopeful about the future of innovative therapies for neurodegenerative diseases. The company’s commitment to transparency and progress is clear, ensuring that both current and prospective investors can continue to engage with their efforts to advance therapeutic solutions in ALS and beyond.
This delisting stems from the company's failure to adhere to the Nasdaq Listing Rule 5550(b)(1), which concerns minimum shareholder equity requirements. Despite this setback, BrainStorm has already taken steps to mitigate the impact of this change. The company has secured approval to have its common stock quoted on the OTCQB Venture Market, a trading platform in the U.S. operated by OTC Markets Group. Trading on OTCQB under the same symbol, BCLI, is expected to commence at the open of trading on July 18, 2025, or shortly thereafter.
Chaim Lebovits, the CEO of BrainStorm Cell Therapeutics, commented on the situation, recognizing the challenges posed by the delisting. He expressed a commitment to their stakeholders, emphasizing that this change does not negatively affect the company's core mission nor its ongoing commitment to advance NurOwn, a promising therapy for amyotrophic lateral sclerosis (ALS) patients. The transition to OTCQB ensures that trading can continue seamlessly, allowing BrainStorm to maintain its focus on the development of NurOwn.
BrainStorm’s NurOwn technology platform represents an innovative approach to treating neurodegenerative diseases. The platform utilizes autologous mesenchymal stem cells (MSCs) that are transformed into neurotrophic factor-secreting cells (MSC-NTF cells). These MSC-NTF cells are designed to release high levels of neurotrophic factors aimed at targeting critical disease pathways in conditions like ALS. The company is gearing up for a pivotal Phase 3b trial under a Special Protocol Assessment (SPA) agreement with the FDA, which promises to advance the clinical development of NurOwn further.
In light of the recent changes, BrainStorm reassured its investors that the delisting will not hinder its business operations or ongoing research initiatives. The company commits to maintaining transparency with its shareholders by providing updates in line with SEC regulations regarding its financial status and other developments.
The transition from Nasdaq to OTCQB illustrates the dynamic nature of the biotechnology landscape, where regulatory compliance and market conditions can shift rapidly. BrainStorm has attracted attention for its ground-breaking research in ALS, which has garnered admiration in both scientific and investor circles. Its commitment to improving patient lives remains unwavering, as they navigate these challenges.
The NurOwn platform has been noted for generating critical insights into ALS, and its clinical program is at the forefront of innovation in this field. BrainStorm's research includes significant findings related to patient genomics and biomarkers, which are vital for understanding and addressing ALS more effectively.
In addition to its ALS endeavors, BrainStorm is making strides in other areas of regenerative medicine. The company is also working on an allogeneic exosome-based platform aimed at delivering therapeutic proteins and nucleic acids. Recently, BrainStorm has achieved a significant milestone with the U.S. Patent and Trademark Office granting a Notice of Allowance for a foundational patent covering its exosome technology. This development fortifies BrainStorm's intellectual property portfolio in the rapidly evolving field of regenerative medicine.
As BrainStorm transitions into its new trading environment, stakeholders are encouraged to remain vigilant and hopeful about the future of innovative therapies for neurodegenerative diseases. The company’s commitment to transparency and progress is clear, ensuring that both current and prospective investors can continue to engage with their efforts to advance therapeutic solutions in ALS and beyond.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.